TAZICEF - VIAL Instructions For Use

(ceftazidime for injection, USP - VIAL)

TEAR AWAY

Tazicef (ceftazidime for injection, USP)
Instructions for Constitution

Vials: 1 g and 2 g

  1. Insert the syringe needle through the vial closure and inject the recommended volume of diluent. The vacuum may assist entry of the diluent. Remove the syringe needle.
  2. Shake to dissolve; a clear solution will be obtained in 1 to 2 minutes.
  3. Invert the vial. Ensuring that the syringe plunger is fully depressed, insert the needle through the vial closure and withdraw the total volume of solution into the syringe (the pressure in the vial may aid withdrawal). Ensure that the needle remains within the solution and does not enter the headspace. The withdrawn solution may contain some bubbles of carbon dioxide.

Note: As with the administration of all parenteral products, accumulated gases should be expressed from the syringe immediately before injection of Tazicef.

Manufactured by Sandoz GmbH for
Hospira, Inc., Lake Forest, IL 60045, USA

LAB-1198-3.0

Revised: 06/2020

Find TAZICEF - VIAL medical information:

Find TAZICEF - VIAL medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

TAZICEF - VIAL Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Instructions For Use

TEAR AWAY

Tazicef (ceftazidime for injection, USP)
Instructions for Constitution

Vials: 1 g and 2 g

  1. Insert the syringe needle through the vial closure and inject the recommended volume of diluent. The vacuum may assist entry of the diluent. Remove the syringe needle.
  2. Shake to dissolve; a clear solution will be obtained in 1 to 2 minutes.
  3. Invert the vial. Ensuring that the syringe plunger is fully depressed, insert the needle through the vial closure and withdraw the total volume of solution into the syringe (the pressure in the vial may aid withdrawal). Ensure that the needle remains within the solution and does not enter the headspace. The withdrawn solution may contain some bubbles of carbon dioxide.

Note: As with the administration of all parenteral products, accumulated gases should be expressed from the syringe immediately before injection of Tazicef.

Manufactured by Sandoz GmbH for
Hospira, Inc., Lake Forest, IL 60045, USA

LAB-1198-3.0

Revised: 06/2020

Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.